Big Bounce - FATEGood Morning,
Looking to see where FATE settles today. There was strong momentum yesterday pushing it out of its bearish trend. As always I keep an eye to see where it settles and then will look for my buy.
Enjoy
FATE trade ideas
13R FATEExpecting a 13R move here.
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biotechnology company specializing in induced pluripotent stem cell (iPSC) technology to develop cellular immunotherapies for cancer and immune disorders. Below are its key fundamentals:
Financial Overview:
Revenue: $3.1M in Q3 2024, primarily from preclinical development collaborations.
Net Loss: $134M in the first three quarters of 2024, reflecting high R&D and administrative expenses.
Cash Position: $297M as of September 2024, with no debt and a cash runway of 2.2 years.
Operating Expenses: $55.5M in Q3 2024, including $34.7M for R&D and $20.8M for general administration.
Key Metrics:
Market Cap: Approximately $191M
Debt-to-Equity Ratio: 0%, indicating no leverage.
Cash Per Share: $5.86, making it an attractive takeover target.
Institutional Ownership: Over 98% of shares.
Challenges:
Declining Revenue: Revenue dropped significantly year-over-year due to reduced collaboration income.
High Cash Burn: Burn rate of $133M annually, though reduced by 28% compared to the previous year.
Speculative Risks: High volatility and likelihood of financial distress within two years.
Outlook:
Fate Therapeutics is focused on advancing its iPSC-based pipeline but faces financial pressure due to declining revenue and ongoing losses. Its strong cash position provides a temporary cushion, but long-term viability depends on successful clinical progress and partnerships.
Whats the fate of FATE?Looking at this US stock,it looks like its at rock bottom.
will FATE rally to $3 or more?
NASDAk pick for today FATE therapeutics STOCK at all time lowswe are practically buying the very dipped stock to ensure low risk and high returns
FATE. Have Faith in this stock.FATE. Have Faith in this stock.
Could snap back to previous channel fast.
Big institional value and insider value.
Gap Down/Bad News Event
No earnings report as of late so I tried to find out what the deal is. Looks like an analyst' downgrade on Friday and some other bad news.
Short is over 24%.
Makes you scratch your head and think WOW!
No recommendation/Dust needs to settle and I guess even dirt can get cheaper )o:
FATE | Incoming Rally - Oversold | LONGFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
FATEFATE is an interesting company, just developing. There are about 480 thousand in cash, an annual loss of 173 thousand, Has 8 studies in 1 phase. Probably, it will “accumulate” one more year before significant phase studies (3), which corresponds to the negative scenario. And 2 in partnership with Janssen and Ono Pharma.
Curious FT596 with rituximab and FT538 with daratumumab, monoclonal antibodies that have been shown to be effective in autoimmune diseases with expiring patents
There is a chance for a rebound from the TA side, we stand at it200, there are divergence boundaries and small ones. It is necessary to wait for the rebound, since there is a possibility of disappearance up to 30.
It can, of course, always abruptly and unexpectedly upward without stopping, these are still scenarios.
Bullish Expecting a sympathy bounce Please review any tips or thoughts is helpful.
1 to 4 risk to reward
Stop loss 69
Short term price target $78
Risking $2 for $8 a share.
FATE Yanagi Lives! Will swing this dead cat bounce3 to 4 weeks on the 30 min chart. Staying patient, hoping bullish wedge forms before the dead cat bounce swing. Some Bollinger band squeezes energy behind it. Let's see!
NASDAQ:FATE
FATE Bullish Triangle Pattern Looking to place some Leaps on FATE as hedge funds pile up on this biotech stock
Very strong setupMRNA leading fate higher, MACD and RSI curling up, A+ setup, im very bullish biotech rn
$FATESetting up in channel with an inverse head and shoulders, buy zone is green box. looking to hold above 100ma to target $122 in the future
Fate Long Theme is the same. Price has made An All Time High. The sky is the limit. Entry Price and SL as stated.
FATE: Bullish PennantBullish Pennant
Pros:
Descending volume during formation
PPS above 50MA and 200MA
RS above 0, and ascending
ATR Ascending
R/R ratio above 5
200MA ascending
250RSI above 50
Price Target:
PT = 145.41$
FATEAnother one looking like a cup and handle! You could be patient wait for a breakout or nibble some here????
